Compare Danaher Corporation (DHR) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Invesco Ltd. — how do they compare? Danaher Corporation trades at $201.61 (market cap $140.88B), while Invesco Ltd. trades at $30.5 (market cap $12.74B). The key difference: Danaher Corporation is far larger — about 11.1× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.99%). Which is the better fit depends on your goals.
| DHR | IVZ | |
|---|---|---|
Market Cap | $140.88B | $12.74B |
Sector | Health | Financials |
52-Week High | $242.05 | $29.44 |
52-Week Low | $161.91 | $16.74 |
Enterprise Value | $153.66B | $22.98B |
Dividend Yield | 0.8% | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
Invesco (IVZ) trades at $28.4, down 2.0% on the day, with a bullish technical signal driven by moving averages. The company reported mixed earnings, beating in Q3 and Q4 2025 but missing in Q1 2026, while revenue grew to $6.38B in 2025. Analyst consensus is a Buy with a $30.50 price target, and recent news highlights upgrades and strong momentum.
The outlook is cautiously optimistic given analyst support and improving cash flow, but risks include negative net income margins and competitive pressures in asset management. Upside hinges on earnings recovery and AUM growth, while macroeconomic volatility remains a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
